Event

PhD Dissertation - John Andrew Quinlan

Monday, September 16, 2024
2:00 p.m.
AJC3104
Rachel Chang
301 405 8268
rachel53@umd.edu

Title: Preparation of a Nanosuspension of the Photosensitizer Verteporfin for Photodynamic and Light-Independent Therapy in Glioblastoma

Committee members:

Dr. Huang-Chiao Huang, Chair

Dr. Michael M. Gottesman

Dr. Jenna L. Mueller

Dr. Helim Aranda-Espinoza

Dr. Wolfgang Losert, Dean's Representative

Abstract:

Photodynamic therapy (PDT) using verteporfin (VP) has treated ocular disease for over 20 years, but recent interest in VP’s light-independent properties has reignited interest in the drug, particularly in glioblastoma (NCT04590664). Separate efforts to apply PDT to glioblastoma using 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) have also garnered attention (NCT03048240), but, unfortunately, clinical trials using 5-ALA-induced PpIX-PDT have yet to yield a survival benefit. Previous studies have shown VP to be a superior PDT agent than 5-ALA-induced PpIX. Our lab has shown that 690 nm light activates VP up to 2 cm into the brain, while 635 nm light only activates PpIX at depths <1 cm into the brain. Additionally, VP is a more effective photosensitizer than PpIX because it has a higher singlet oxygen yield and is active in the vasculature as well as target tumor cells. However, the hydrophobicity of VP limits effective delivery of the drug to the brain for treatment of glioblastoma.

In this context, this thesis aims to re-evaluate the delivery method for VP. VP traditionally requires lipids for delivery as Visudyne®. Recent shortages of Visudyne® and potential drawbacks of liposomal carriers motivated our development of a carrier-free nanosuspension of verteporfin, termed NanoVP. Previous work has shown that cellular uptake of VP is greater when delivered as NanoVP rather than liposomal VP, resulting in improved cell killing after light activation.

This thesis builds on this previous work by (1) evaluating synthesis and storage parameters for NanoVP, (2) determining the pharmacokinetics, biodistribution, and brain bioavailability of NanoVP, and (3) evaluating the potential efficacy of NanoVP as a PDT and a chemotherapy agent, and by supporting development of a zebrafish model of the blood-brain barrier for mechanistic studies of improved drug delivery to the brain.